

## Exonhit's extraordinary shareholders' meeting

- Shareholders approved all resolutions proposed by the Management Board
- ExonHit Therapeutics is now called "Exonhit"

**Paris, France – May 18, 2011** – At the extraordinary shareholders' meeting held today with a quorum of 23.97%, Exonhit's shareholders approved all resolutions proposed by the Management Board.

Specifically, shareholders approved:

- the change of name: ExonHit Therapeutics becomes Exonhit;
- the authorization granted to the Management Board to issue free warrants for the benefit of the six members of the Supervisory Board;
- the authorization granted to the Management Board to proceed with a share capital increase for the benefit of the employees as part of the employees' saving plan.

"The change of name is for simplification, but reflects primarily our strategy which is to become a key player in personalized medicine through the development of biomarkers and companion diagnostics in partnership with the pharmaceutical industry," said Loïc Maurel, M.D., Chairman of the Management Board at Exonhit.

### About Exonhit

Exonhit (Alternext: ALEHT) is a biotech company, focused on personalized medicine, which develops targeted innovative therapeutic and diagnostic products, in oncology and Alzheimer's disease. Exonhit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with Allergan.

Exonhit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris and is part of the NYSE Alternext OSEO innovation index. For more information, please visit <http://www.exonhit.com>.

### Disclaimer

*This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.*

*In addition, Exonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.*

*Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.*

**Contact for Media & Investors**

Corinne Hoff

+33 1 58 05 47 04

[corinne.hoff@exonhit.com](mailto:corinne.hoff@exonhit.com)